JP2024543477A5 - - Google Patents
Info
- Publication number
- JP2024543477A5 JP2024543477A5 JP2024528452A JP2024528452A JP2024543477A5 JP 2024543477 A5 JP2024543477 A5 JP 2024543477A5 JP 2024528452 A JP2024528452 A JP 2024528452A JP 2024528452 A JP2024528452 A JP 2024528452A JP 2024543477 A5 JP2024543477 A5 JP 2024543477A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- cycloalkyl
- heterocycloalkyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021130290 | 2021-11-12 | ||
| CNPCT/CN2021/130290 | 2021-11-12 | ||
| CN2022123827 | 2022-10-08 | ||
| CNPCT/CN2022/123827 | 2022-10-08 | ||
| PCT/CN2022/131293 WO2023083286A1 (en) | 2021-11-12 | 2022-11-11 | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543477A JP2024543477A (ja) | 2024-11-21 |
| JP2024543477A5 true JP2024543477A5 (https=) | 2025-11-19 |
Family
ID=86335131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024528452A Pending JP2024543477A (ja) | 2021-11-12 | 2022-11-11 | ユビキチン特異的プロテアーゼ１（ｕｓｐ１）の小分子阻害剤及びその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20250026754A1 (https=) |
| EP (1) | EP4430050A4 (https=) |
| JP (1) | JP2024543477A (https=) |
| KR (1) | KR20240117556A (https=) |
| CN (1) | CN119053601A (https=) |
| AR (1) | AR127646A1 (https=) |
| AU (1) | AU2022386486A1 (https=) |
| CA (1) | CA3235765A1 (https=) |
| CL (2) | CL2024001397A1 (https=) |
| CO (1) | CO2024006269A2 (https=) |
| CR (1) | CR20240191A (https=) |
| DO (1) | DOP2024000080A (https=) |
| GE (1) | GEAP202416532A (https=) |
| IL (1) | IL312642A (https=) |
| JO (1) | JOP20240096A1 (https=) |
| MX (1) | MX2024005755A (https=) |
| PE (1) | PE20241307A1 (https=) |
| TW (1) | TW202334142A (https=) |
| WO (1) | WO2023083286A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312642A (en) | 2021-11-12 | 2024-07-01 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| EP4605391A1 (en) * | 2022-10-21 | 2025-08-27 | Exelixis, Inc. | 4,5,6,7-tetrahydro-1-pyrazolo[4,3-c]pyridine compounds and derivatives as usp1 inhibitors |
| WO2025010245A1 (en) | 2023-07-06 | 2025-01-09 | Exelixis, Inc. | Fused pyrazole derivatives as usp1 inhibitors |
| TW202519226A (zh) | 2023-11-08 | 2025-05-16 | 美商艾克塞里克斯公司 | 使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法 |
| WO2025102016A1 (en) | 2023-11-10 | 2025-05-15 | Vrise Therapeutics, Inc. | Novel molecules as inhibitors of dna damage repair pathway |
| TW202539659A (zh) | 2024-01-10 | 2025-10-16 | 美商維瑞斯治療股份有限公司 | Ｄｎａ損傷修復途徑的新穎抑制劑 |
| WO2025227060A1 (en) | 2024-04-26 | 2025-10-30 | Insilico Medicine Ip Limited | Heterocyclic inhibitors of ubiquitin specific protease 1 (usp1) in combination with additional agents for use in the treatment of cancer |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4337611A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| NZ511674A (en) * | 1998-12-23 | 2003-11-28 | Du Pont Pharm Co | Nitrogen containing heterobicycles as factor Xa inhibitors |
| JP4166991B2 (ja) | 2001-02-26 | 2008-10-15 | 田辺三菱製薬株式会社 | ピリドピリミジンまたはナフチリジン誘導体 |
| JP2004083587A (ja) | 2002-08-06 | 2004-03-18 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| ITFR20030005U1 (it) | 2003-03-17 | 2003-06-16 | C D R | Sistema di protezione solare (frangisole f1) |
| JP2010208945A (ja) | 2007-06-01 | 2010-09-24 | Mitsubishi Tanabe Pharma Corp | 複素環化合物 |
| JP5063815B2 (ja) | 2008-11-25 | 2012-10-31 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体 |
| MX2012004846A (es) | 2009-10-29 | 2012-10-05 | Genosco | Inhibidores de cinasa. |
| RU2012131124A (ru) | 2009-12-23 | 2014-01-27 | Элан Фармасьютикалз, Инк. | Птеридиноны как ингибиторы polo-подобных киназ |
| WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| US9242981B2 (en) * | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| AU2011376721B2 (en) | 2011-09-16 | 2017-06-08 | Sanofi | Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them |
| EP2938610A2 (en) | 2012-12-28 | 2015-11-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
| CN104311555B (zh) | 2014-09-19 | 2016-04-20 | 广东东阳光药业有限公司 | 吡唑并哌啶酮类化合物及其组合物及用途 |
| EP3632915A1 (en) | 2014-11-27 | 2020-04-08 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| CN108473495B (zh) | 2015-11-20 | 2022-04-12 | 福马治疗有限公司 | 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮 |
| SG11201804901WA (en) | 2015-12-22 | 2018-07-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| JP7014736B2 (ja) | 2016-05-24 | 2022-02-01 | ジェネンテック， インコーポレイテッド | がんの処置のためのピラゾロピリジン誘導体 |
| EA201992780A1 (ru) | 2017-06-21 | 2020-06-02 | ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи | Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания |
| US11413288B2 (en) | 2017-11-01 | 2022-08-16 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancers |
| US11485736B2 (en) * | 2018-12-20 | 2022-11-01 | KSQ Therapeutics, Inc. | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors |
| US20220073525A1 (en) * | 2018-12-28 | 2022-03-10 | Forma Therapeutics, Inc. | Compositions for inhibiting ubiquitin specific protease 1 |
| WO2021163530A1 (en) * | 2020-02-14 | 2021-08-19 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
| EP4161494A4 (en) | 2020-06-02 | 2024-07-17 | KSQ Therapeutics, Inc. | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS |
| KR20230098186A (ko) | 2020-10-30 | 2023-07-03 | 케이에스큐 세러퓨틱스 인코포레이티드 | 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도 |
| WO2022174031A1 (en) | 2021-02-12 | 2022-08-18 | Relay Therapeutics, Inc. | Cdk inhibitors and methods of use thereof |
| EP4291559A1 (en) | 2021-02-15 | 2023-12-20 | Tango Therapeutics, Inc. | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer |
| WO2022197892A1 (en) | 2021-03-17 | 2022-09-22 | Tango Therapeutics, Inc. | Purine derivatives as anticancer agents |
| WO2022199652A1 (en) | 2021-03-24 | 2022-09-29 | Impact Therapeutics (Shanghai) , Inc | Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof |
| CA3214040A1 (en) | 2021-04-07 | 2022-10-13 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 1 (usp1) |
| CN117136189A (zh) | 2021-04-09 | 2023-11-28 | 先声再明医药有限公司 | 泛素特异性蛋白酶1（usp1）抑制剂 |
| EP4430041A4 (en) | 2021-11-12 | 2025-09-24 | Insilico Medicine Ip Ltd | SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) AND THEIR USES |
| IL312642A (en) | 2021-11-12 | 2024-07-01 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| EP4430049A4 (en) | 2021-11-12 | 2025-12-17 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof |
| EP4605391A1 (en) | 2022-10-21 | 2025-08-27 | Exelixis, Inc. | 4,5,6,7-tetrahydro-1-pyrazolo[4,3-c]pyridine compounds and derivatives as usp1 inhibitors |
-
2022
- 2022-11-11 IL IL312642A patent/IL312642A/en unknown
- 2022-11-11 AR ARP220103104A patent/AR127646A1/es unknown
- 2022-11-11 WO PCT/CN2022/131293 patent/WO2023083286A1/en not_active Ceased
- 2022-11-11 AU AU2022386486A patent/AU2022386486A1/en active Pending
- 2022-11-11 MX MX2024005755A patent/MX2024005755A/es unknown
- 2022-11-11 KR KR1020247018882A patent/KR20240117556A/ko active Pending
- 2022-11-11 US US18/709,234 patent/US20250026754A1/en not_active Abandoned
- 2022-11-11 CA CA3235765A patent/CA3235765A1/en active Pending
- 2022-11-11 CR CR20240191A patent/CR20240191A/es unknown
- 2022-11-11 GE GEAP202416532A patent/GEAP202416532A/en unknown
- 2022-11-11 EP EP22892079.9A patent/EP4430050A4/en active Pending
- 2022-11-11 TW TW111143088A patent/TW202334142A/zh unknown
- 2022-11-11 CN CN202280087378.2A patent/CN119053601A/zh active Pending
- 2022-11-11 PE PE2024001033A patent/PE20241307A1/es unknown
- 2022-11-11 JP JP2024528452A patent/JP2024543477A/ja active Pending
-
2023
- 2023-02-06 US US18/106,339 patent/US11739077B2/en active Active
- 2023-06-26 US US18/340,978 patent/US12570634B2/en active Active
-
2024
- 2024-04-24 JO JOJO/P/2024/0096A patent/JOP20240096A1/ar unknown
- 2024-05-09 CL CL2024001397A patent/CL2024001397A1/es unknown
- 2024-05-10 DO DO2024000080A patent/DOP2024000080A/es unknown
- 2024-05-17 CO CONC2024/0006269A patent/CO2024006269A2/es unknown
-
2025
- 2025-04-09 CL CL2025001068A patent/CL2025001068A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024543477A5 (https=) | ||
| JP2024543475A5 (https=) | ||
| KR101694383B1 (ko) | 이미다조피롤리디논 화합물 | |
| EP2855483B1 (en) | Pyrrolopyrrolidinone compounds | |
| HK1245780A1 (en) | Imidazopyrrolidinone compounds | |
| DK2451794T3 (en) | 1,2,4-thiazolidin-3-ONE DERIVATIVES AND THEIR USE IN CANCER TREATMENT | |
| JP2005514398A5 (https=) | ||
| WO2020223538A1 (en) | Substituted cycloalkyls as modulators of the integrated stress pathway | |
| JP2013508378A5 (https=) | ||
| JP2008523041A5 (https=) | ||
| ES2566482T3 (es) | Derivados de oxazol sustituidos, composición farmacéutica que contiene los derivados, y método para tratar la enfermedad de Parkinson utilizando los mismos | |
| CA3080959A1 (en) | Modulators of the integrated stress pathway | |
| CN104822373A (zh) | 治疗性化合物和组合物 | |
| CA2917096A1 (en) | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors | |
| JP2007505933A5 (https=) | ||
| JP2014500322A5 (https=) | ||
| JP2011507849A5 (https=) | ||
| JP2010504346A5 (https=) | ||
| JP2003525872A5 (https=) | ||
| JP2011526917A5 (https=) | ||
| JP2022511477A5 (https=) | ||
| JP2014507443A5 (https=) | ||
| RU2016111138A (ru) | Гетероциклические соединения и способы их применения | |
| JP2024516033A5 (https=) | ||
| JP2021514011A5 (https=) |